(PharmaNewsWire.Com, March 06, 2018 ) Researchers are focusing on launching pipeline molecules for acromegaly and gigantism and most of these molecules are in Phase III stage of development. The availability of a large number of molecules in pipeline is resulting in an increased consumption of gigantism and acromegaly drugs. According to Publisher’s market research report, the presence of a strong pipeline will be one of the primary factors driving the growth of the acromegaly and gigantism drugs market till 2022. Numerous companies are trying to meet the medical needs for this condition by focusing more on the drug development. Pasireotide long-acting release (LAR) by Novartis and octreotide capsules by Chiasma are in the Phase III stage of development for the treatment of acromegaly. They are targeted at individuals with acromegaly who are inadequately treated with the combination therapy of lanreotide autogel and pegvisomant by Ipsen and somatostatin analogs. This in turn, results in a strong pipeline for gigantism and acromegaly treatment. Publisher’s market research analysts have predicted that this global market will register a revenue of close to USD 1.4 billion by 2022.
Covered in this report The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.
The market is divided into the following segments based on geography: -Americas -APAC -EMEA
Publisher's report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Market challenge -Difficulty in diagnosis -For a full, detailed list, view our report
Market trend -Growing popularity of drugs over surgeries -For a full, detailed list, view our report
Table of Contents
PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE PART 05: MARKET SIZING PART 06: FIVE FORCES ANALYSIS PART 07: MARKET SEGMENTATION PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE PART 14: VENDOR ANALYSIS PART 15: APPENDIX
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
